logo
Hollywood isn't ready for AI. These people are diving in anyway

Hollywood isn't ready for AI. These people are diving in anyway

When filmmakers say they're experimenting with artificial intelligence, that news is typically received online as if they had just declared their allegiance to Skynet.
And so it was when Darren Aronofsky — director of button-pushing movies including 'The Whale' and 'Black Swan' — last week announced a partnership with Google AI arm DeepMind to use the tech giant's capabilities in storytelling.
Aronofsky's AI-focused studio Primordial Soup is producing three short movies from emerging filmmakers using Google tools, including the text-to-video model Veo. The first film, 'Ancestra,' directed by Eliza McNitt, will premiere at the Tribeca Festival on June 13, the Mountain View-based search giant said.
Google's promotional materials take pains to show that 'Ancestra' is a live-action film made by humans and with real actors, though it's bolstered with effects and imagery — including a tiny baby holding a mother's finger — that were created with AI.
The partnership was touted during Google's I/O developer event, where the company showed off the new Veo 3, which allows users to create videos that include sound effects, ambient noise and speech (a step up from OpenAI-owned competitor, Sora). The company also introduced its new Flow film creation tool, essentially editing software using Google AI functions.
Google's push to court creative types coincides with a separate initiative to help AI technology overcome its massive public relations problem.
As my colleague Wendy Lee wrote recently, the company is working with filmmakers including Sean Douglas and his famous father Michael Keaton to create shorts that aren't made with AI, but instead portray the technology in a less apocalyptic light than Hollywood is used to.
Simply put, much of the public sees AI as a foe that will steal jobs, rip off your intellectual property, ruin your childhood, destroy the environment and possibly kill us all, like in 'The Terminator,' '2001: A Space Odyssey' and the most recent 'Mission: Impossible' movies. And Google, which is making a big bet by investing in AI, has a lot riding on changing that perception.
There's a ways to go, including in the entertainment industry.
Despite the allure of cost-savings, traditional studios haven't exactly dived headfirst into the AI revolution. They're worried about the legal implications of using models trained on troves of copyrighted material, and they don't want to anger the entertainment worker unions, which went on strike partly over AI fears just a couple years ago. The New York Times and others have sued OpenAI and its investor Microsoft, alleging copyright theft. Tech giants claim they are protected by 'fair use.'
AI-curious studios are walking into a wild, uncharted legal landscape because of the amount of copyrighted material being mined to teach the models, said Dan Neely, co-founder of startup Vermillio, which helps companies and individuals protect their intellectual property.
'The major studios and most people are going to be challenged using this product when it comes to the output content that you can and cannot use or own,' Neely said by phone. 'Given that it contains vast quantities of copyrighted material, and you can get it to replicate that stuff pretty easily, that creates chaos for someone who's creating with it.'
But while the legacy entertainment business remains largely skeptical of AI, many newer, digitally-native studios and creators are embracing it, whether their goals are to become the next Pixar or the next Mr. Beast.
The New York Times recently profiled the animation startup Toonstar, which says it uses AI throughout its production process, including when sharpening storylines and lip-syncing. John Attanasio, a Toonstar founder, told the paper that leaning into the tech would make animation '80 percent faster and 90 percent cheaper than industry norms.'
Jeffrey Katzenberg, the former leader of DreamWorks Animation, has given a similar estimate of the potential cost-savings for Hollywood cartoons.
Anyone working in the traditional computer animation business would have to gulp at those projections, whether they turn out to be accurate or not. U.S. animation jobs have already been hammered by outsourcing. Now here comes automation to finish the job. (Disney's animated features cost well over $100 million to produce because they're made by real-life animators in America.)
Proponents of AI will sometimes argue that the new technology isn't a replacement for human workers, but rather a tool to enhance creativity. Some are more blunt: Stop worrying about these jobs and embrace the future of uninhibited creation. For obvious reasons, workers are reluctant to buy into that line of thinking.
More broadly, it's still unclear whether all the spending on the AI arms race will ultimately be worth the cost. Goldman Sachs, in a 2024 report, estimated that companies would invest $1 trillion in AI infrastructure — including data centers, chips and the power grid — in the coming years.
But that same report raised questions about AI's ultimate utility.
To be worth the gargantuan investment, the technology would have to be capable of solving far more complex problems than it does now, said one Goldman analyst in the report. In recent weeks, the flaws in the technology have crossed over into absurd territory: For example, by generating a summer reading list of fake books and legal documents polluted with serious errors and fabrications.
Big spending and experimentation doesn't always pan out. Look at virtual reality, the metaverse and the blockchain.
But some entertainment companies are experimenting with the tools and finding applications. Meta has partnered with horror studio Blumhouse and James Cameron's venture Lightstorm Vision on AI-related initiatives. AI firm Runway is working with Lionsgate. At a time when the movie industry is troubled in part due to the high cost of special effects, production companies are motivated to stay on top of advancing tech.
One of the most common arguments in favor of giving in to AI is that the technology will unshackle the next generation of creative minds.
Some AI-enhanced content is promising. But so far AI video tools have produced a remarkable amount of content that looks the same, with its oddly dreamlike sheen of unreality. That's partly because the models are trained on color-corrected imagery available on the open internet or on YouTube. Licensing from the studios could help with that problem.
The idea of democratizing filmmaking through AI may sound good in theory. However, there are countless examples in movie history — including 'Star Wars' and 'Jaws' — of how having physical and budgetary restrictions are actually good for art, however painful and frustrating they may have been during production.
Even within the universe of AI-assisted material, the quality will vary dramatically depending on the talent and skill of people using it.
'Ultimately, it's really hard to tell good stories,' Neely said. 'The creativity that defines what you prompt the machine to do is still human genius — the best will rise to the top.'
Like other innovations, the technology will improve with time, as the new Google tools show. Both Veo 3 and Flow showcase how AI is becoming better and easier to use, though they are still not quite mass-market products. For its highest tier, Google is charging $250 a month for its suite of tools.
Maybe the next Spielberg will find their way through AI-assisted video, published for free on YouTube. Perhaps Sora and Veo will have a moment that propels them to mainstream acceptance in filmmaking, as 'The Jazz Singer' did for talkies.
But those milestones still feel a long way off.
The Memorial Day weekend box office achieved record revenue (not adjusting for inflation) of $329.8 million in the U.S. and Canada, thanks to the popularity of Walt Disney Co.'s 'Lilo & Stitch' and Paramount's 'Mission: Impossible — The Final Reckoning.'
Disney's live-action remake generated $183 million in domestic ticket sales, exceeding pre-release analyst expectations, while the latest Tom Cruise superspy spectacle opened with $77 million. The weekend was a continuation of a strong spring rebound for theaters. Revenue so far this year is now up 22% versus 2024, according to Comscore.
This doesn't mean the movie business is saved, but it does show that having a mix of different kinds of movies for multiple audiences is healthy for cinemas. Upcoming releases include 'Karate Kid: Legends,' 'Ballerina,' 'How to Train Your Dragon' and a Pixar original, 'Elio.'
'Lilo & Stitch' is particularly notable, coming after Disney's previous live-action redo, 'Snow White,' bombed in theaters. While Snow White has an important place in Disney history, Stitch — the chaotic blue alien — has quietly become a hugely important character for the company, driving enormous merchandise sales over the years.
The 2002 original wasn't a huge blockbuster, coming during an awkward era for Walt Disney Animation, but the remake certainly is.
Watch: Prepping for the new 'Naked Gun' by rewatching the classic and reliving the perfect Twitter meme.
Listen: My favorite episode of 'Blank Check with Griffin & David' in a long time — covering Steven Spielberg's 'Hook' with Lin-Manuel Miranda.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Google and DOJ to make final push in US search antitrust case
Google and DOJ to make final push in US search antitrust case

Yahoo

time30 minutes ago

  • Yahoo

Google and DOJ to make final push in US search antitrust case

By Jody Godoy WASHINGTON (Reuters) -Alphabet's Google and U.S. antitrust enforcers will make their final arguments on whether the tech giant should be forced to sell its Chrome browser or adopt other measures to restore competition in online search, as the blockbuster antitrust trial concludes on Friday. The U.S. Department of Justice and a coalition of states are pressing to make Google not only sell Chrome, but also share search data and cease multibillion-dollar payments to Apple and other smartphone makers and wireless carriers that set Google as the default search engine on new devices. The proposals aim to restore competition after a judge found last year that Google illegally dominates the online search and related advertising markets. Artificial intelligence companies could get a boost after already rattling Google's status as the go-to tool to find information online. U.S. District Judge Amit Mehta is overseeing the trial, which began in April. He has said he aims to rule on the proposals by August. If the judge does require Google to sell off Chrome, OpenAI would be interested in buying it, Nick Turley, OpenAI's product head for ChatGPT, said at the trial. OpenAI would also benefit from access to Google's search data, which would help it make responses to user inquiries more accurate and up to date, Turley said. Google says the proposals go far beyond what is legally justified by the court's ruling, and would give away its technology to competitors. The company has already begun loosening agreements with smartphone makers including Samsung Electronics to allow them to load rival search and AI products. The DOJ wants the judge to go farther, banning Google from making lucrative payments in exchange for installation of its search app. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating
Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating

Yahoo

time31 minutes ago

  • Yahoo

Raymond James Lifts Coherent Corp. (COHR)'s Stock Price Target to $96, Maintains Strong Buy Rating

Raymond James analyst Simon Leopold on Wednesday raised Coherent Corp. (NYSE:COHR)'s stock price target to $96 from $91, while maintaining the Strong Buy rating for its shares. The revision followed Coherent Corp. (NYSE:COHR)'s Analyst and Investor Day earlier in the day, in which the company shared its long-term growth targets that surpassed both Raymond James' and the broader market's expectations. A row of precision industrial lasers in action, cutting the most intricate of shapes. Coherent Corp. (NYSE:COHR)'s management outlined its goals, such as aiming for a gross margin greater than 42% and an operating margin above 24%, indicating that by 2028, the company could achieve an EPS of around $8-9, which will be a substantial increase from forecasts of under $4 in fiscal 2025. Considering these ambitious targets, Raymond James lifted the stock's target price to account for the anticipated gross margin expansion and growth in the industrial laser sector. Moreover, on May 7, Coherent Corp. (NYSE: COHR) reported impressive results for the third quarter of fiscal 2025, with revenue increasing 24% year-over-year to $1.5 billion, driven by strong demand for AI-related data centers. Earnings per share were posted at $0.91, beating estimates by five cents. While we acknowledge the potential of COHR as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than COHR and that has 100x upside potential, check out our report about this cheapest AI stock. READ NEXT: ChatGPT Stock Advice: Top 12 Stock Recommendations and 10 Cheap Rising Stocks to Buy Right Now. Disclosure: None.

AI Tool Linked to Fewer Recurrent Events After Stroke
AI Tool Linked to Fewer Recurrent Events After Stroke

Medscape

time33 minutes ago

  • Medscape

AI Tool Linked to Fewer Recurrent Events After Stroke

HELSINKI, Finland — An artificial intelligence (AI)–based clinical decision support system helped doctors make decisions in the treatment of acute ischemic stroke and was associated with a significant reduction in recurrent vascular events in a new, randomized trial. The AI system integrated clinician input with data from the hospital records and imaging of more than 20,000 patients in China to help guide patient management around stroke etiology and secondary prevention. The trial represents a strong case for the future role of AI in stroke care, said Study Chair, Li Zhang, MD, Beijing Tiantan Hospital, Capital Medical University, Beijing, China. 'By harnessing AI to deliver rapid, evidence-based guidance, we've shown that decision support can move beyond theory into practice — improving both how we treat acute strokes and the lives of our patients.' However, experts not involved in the study noted that the research is based on Chinese stroke guidelines — which differ from guidelines in the United States and United Kingdom — and would need to be replicated in the West before use. Zhang presented the results of the GOLDEN BRIDGE II trial on May 22 at the European Stroke Organization Conference (ESOC) 2025. A Test of AI in Stroke Management Rapid and accurate decision-making is critical in acute stroke management, and AI tools offering automated imaging analysis, stroke subtype classification, and guideline-based treatment recommendations, hold promise for standardizing care and improving outcomes, Zhang noted. The GOLDEN BRIDGE II trial was designed to test this hypothesis in a real-world, multicenter setting. The trial, which had a cluster randomized design, was conducted from January 2021 to June 2023 in 77 hospitals in China. The hospitals were randomized to use the AI support system or to continue usual care. The AI system provided automated MRI lesion detection and lesion characteristics analysis, algorithmic classification of stroke etiology and pathogenesis, with real-time, guideline-based recommendations for secondary prevention. The trial included 21,603 patients with acute ischemic stroke (median age, 67 years; 35% women), with 96% completing a 12-month follow-up. The primary endpoint was the occurrence of new vascular events (composite of ischemic stroke, hemorrhagic stroke, myocardial infarction, or vascular death) at 3 months after stroke onset. A 'Strong Case' Results showed that patients for whom the AI model was used had significantly fewer recurrent vascular events at all three time points evaluated. Rates of recurrent vascular events in the intervention group vs the control group were 2.9% vs 3.9% (adjusted hazard ratio [aHR], 0.71; P < .001) at 3 months; 3.4% vs 4.8% (aHR, 0.70; P < .001) at 6 months; and 4.0% vs 5.5% (aHR, 0.70; P < .001) at 12 months. The use of the AI tool was also associated with a lower all-cause mortality at 6 months (2.0% vs 2.3%; aHR, 0.78; P = .007) and at 12 months (3.0% vs 3.5%; aHR 0.77; P < .001). In addition, patients at the hospitals using the AI tool were more likely to achieve a higher composite acute ischemic stroke quality score (91.4 % vs 89.7 %; odds ratio, 1.26; P < .001). A potential limitation of the study was the cluster randomized design, which could allow variations in care between hospitals to influence the results. But Zhang concluded that the trial represents a strong case for the future role of AI in stroke care, saying that the findings 'support wider adoption of AI-driven decision support to optimize acute stroke care and patient outcomes globally.' Not Ready for Routine Clinical Use Commenting on the findings during a discussion on the GOLDEN BRIDGE II trial, Carlos Molina, MD, head of Neurology at Vall d'Hebron Hospital, Barcelona, Spain, noted several study strengths, including the large study cohort and the clinical and technological validation of the sophisticated AI system used in the trial. 'This is an important step,' he added, 'but there are always concerns when we think about trying to integrate AI into clinical practice.' Georgios Tsivgoulis, MD, professor of neurology at the National and Kapodistrian University of Athens, Athens, Greece, noted that although there was a substantial reduction in vascular events and recurrent strokes in the intervention group, the mechanisms that led to this reduction were not clear. 'How did the AI improve clinical practice? Was it through imaging, was it because of better adherence to the Chinese stroke guidelines or was it related to better stroke subtype classification and perhaps treatment individualization? I would like to see more information about the step between the AI implementation and the event reduction results,' he commented. Karin Klijn, professor and chair of neurology at Radboud University Medical Center, Nijmegen, the Netherlands, said the improvement in recurrent events appeared to be driven by the imaging. 'But we didn't hear any details, and we need to see more details so we can see where improvements can be made.' 'However, this was an impressive study in that it involved more than 70 hospitals and more than 20,000 patients. I think AI will help us to achieve the same level of confidence for all the images we have to examine and decisions we have made. I see great potential for this technology,' Klijn added. The trial would also need to be replicated in the Western world for the AI tool to be used in Europe or North America, Tsivgoulis said. 'The GOLDEN BRIDGE II trial is based on the Chinese stroke guidelines which are substantially different from European and US stroke guidelines,' he pointed out. 'It would need to be replicated in Europe and North America using standardized European Stroke Organization and American Stroke Association guidelines to see if this huge beneficial effect can be replicated in Western patients.' Molina agreed, adding that 'the data sources used to train this model are critical to avoid bias that AI can amplify.' In the future, more complex large language models will be available that involve real time interaction with the user and include reinforcing learning, Molina added. 'This prototype is evolving and interaction with the user is critical. There is a lot to learn about that. But this is the first step,' he said. Also commenting, Alastair Webb, MD, clinical reader in stroke medicine at Imperial College London, London, England, also had questions on how it could be implemented in practice. 'This study was designed a few years ago and has taken years to produce these results. How do we keep the algorithm updated and incorporate the continuous changes in clinical practice that occur? We can't do a trial for every update. So we are going to have to integrate this technology into our systems with some sort of real time method of assessing whether every new evolution doesn't cause harm, doesn't make the wrong decision in a large language model.'

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store